BR9710704A - Uso de inibidores de proteina cinase c para aumentar a efic cia cl¡nica de agentes oncol¡ticos e terapia de radia-Æo - Google Patents

Uso de inibidores de proteina cinase c para aumentar a efic cia cl¡nica de agentes oncol¡ticos e terapia de radia-Æo

Info

Publication number
BR9710704A
BR9710704A BR9710704A BR9710704A BR9710704A BR 9710704 A BR9710704 A BR 9710704A BR 9710704 A BR9710704 A BR 9710704A BR 9710704 A BR9710704 A BR 9710704A BR 9710704 A BR9710704 A BR 9710704A
Authority
BR
Brazil
Prior art keywords
inhibitors
protein kinase
radiation therapy
clinical efficacy
increase clinical
Prior art date
Application number
BR9710704A
Other languages
English (en)
Inventor
Michael R Jirousek
Lawrence E Stramm
Douglas Kirk Ways
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9710704A publication Critical patent/BR9710704A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9710704A 1996-05-01 1997-05-01 Uso de inibidores de proteina cinase c para aumentar a efic cia cl¡nica de agentes oncol¡ticos e terapia de radia-Æo BR9710704A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1665896P 1996-05-01 1996-05-01
US08/841,738 US6232299B1 (en) 1996-05-01 1997-04-30 Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
PCT/US1997/007801 WO1997040842A1 (en) 1996-05-01 1997-05-01 Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy

Publications (1)

Publication Number Publication Date
BR9710704A true BR9710704A (pt) 1999-08-17

Family

ID=26688914

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710704A BR9710704A (pt) 1996-05-01 1997-05-01 Uso de inibidores de proteina cinase c para aumentar a efic cia cl¡nica de agentes oncol¡ticos e terapia de radia-Æo

Country Status (15)

Country Link
US (3) US6232299B1 (pt)
EP (1) EP0914135A4 (pt)
JP (1) JP2000510828A (pt)
KR (1) KR20000065223A (pt)
AU (1) AU718098B2 (pt)
BR (1) BR9710704A (pt)
CA (1) CA2253263A1 (pt)
CZ (1) CZ344398A3 (pt)
EA (1) EA199800971A1 (pt)
HU (1) HUP0100285A3 (pt)
IL (1) IL126768A0 (pt)
NO (1) NO985065L (pt)
NZ (1) NZ332563A (pt)
PL (1) PL330862A1 (pt)
WO (1) WO1997040842A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
CA2526617C (en) 2003-05-20 2015-04-28 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
AU2004259760B9 (en) 2003-07-23 2011-02-03 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CN1898240B (zh) 2003-10-15 2011-08-03 Osi制药公司 咪唑并吡嗪类酪氨酸激酶抑制剂
ATE433979T1 (de) 2004-04-02 2009-07-15 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US20060228734A1 (en) * 2005-03-18 2006-10-12 Applera Corporation Fluid processing device with captured reagent beads
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
KR20080046161A (ko) * 2005-08-09 2008-05-26 요하네스 구텐베르크-유니버시타트 마인츠 비-소세포 폐암의 치료를 위한 스타우로스포린 유도체
US20070112053A1 (en) 2005-09-16 2007-05-17 Pickett Cecil B Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP2179037A4 (en) 2007-08-21 2010-12-22 Nodality Inc DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES
EP2050441A1 (en) * 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
WO2009091939A1 (en) * 2008-01-18 2009-07-23 Osi Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
WO2009134944A2 (en) * 2008-04-29 2009-11-05 Nodality, Inc. Methods of determining the health status of an individual
JP2011520970A (ja) * 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
EP2304436A1 (en) 2008-07-10 2011-04-06 Nodality, Inc. Methods for diagnosis, prognosis and treatment
US8399206B2 (en) * 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
MX2011011025A (es) 2009-04-20 2011-11-02 Osi Pharmaceuticals Llc Preparacion de c-piracin-metilaminas.
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
WO2010135608A1 (en) * 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
AU2012214405B2 (en) 2011-02-11 2015-07-23 Glaxosmithkline Intellectual Property Development Limited Cathepsin C inhibitors
WO2012173841A1 (en) * 2011-06-07 2012-12-20 Dana-Farber Cancer Institute, Inc. Biomarker for pkc-iota activity and methods of using same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937232A (en) 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
IL89167A (en) 1988-02-10 1994-02-27 Hoffmann La Roche Substituted pyrroles, their manufacture and pharmaceutical compositions containing them
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US4990519A (en) 1988-10-24 1991-02-05 Merrell Dow Pharmaceuticals Method of using quinolyloxazole-2-ones as proteinkinase C inhibitors
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5204370A (en) 1990-11-05 1993-04-20 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
US5141957A (en) 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
AU637014B2 (en) * 1990-11-02 1993-05-13 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase c
JPH06510280A (ja) * 1991-08-22 1994-11-17 スフィンクス・ファーマスーティカルズ・コーポレーション タンパクキナーゼｃ阻害および新規化合物バラノール
US5216014A (en) 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors
US5270310A (en) 1991-12-13 1993-12-14 Sphinx Pharmaceuticals Corporation N-aminoalkyl amide inhibitors of protein kinase C
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
DE69410814T2 (de) 1993-10-18 1998-11-12 Virginia Tech Intell Prop Synthese von sphingosinen
DE69418978T2 (de) 1993-12-07 1999-10-28 Eli Lilly And Co., Indianapolis Synthese von Bisindolylmaleimiden
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
ATE456367T1 (de) * 1993-12-23 2010-02-15 Lilly Co Eli Proteinkinase c inhibitoren
JPH10501527A (ja) * 1994-06-01 1998-02-10 チバ−ガイギー アクチェンゲゼルシャフト 多重薬剤耐性細胞を抗腫瘍剤に対して感受性にするためのインドロカルバゾール誘導体
US5491242A (en) 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5432198A (en) * 1994-08-18 1995-07-11 Sphinx Pharmaceuticals Corporation Vicinal-substituted carbocyclic compounds as therapeutic agents
US5616577A (en) 1994-08-25 1997-04-01 Smithkline Beecham Corporation Protein Kinase C inhibitor

Also Published As

Publication number Publication date
US6486179B2 (en) 2002-11-26
AU718098B2 (en) 2000-04-06
NZ332563A (en) 2000-08-25
WO1997040842A1 (en) 1997-11-06
CZ344398A3 (cs) 1999-07-14
AU3000297A (en) 1997-11-19
PL330862A1 (en) 1999-06-07
US6288053B1 (en) 2001-09-11
HUP0100285A2 (hu) 2001-09-28
US20010001791A1 (en) 2001-05-24
JP2000510828A (ja) 2000-08-22
EA199800971A1 (ru) 1999-04-29
US6232299B1 (en) 2001-05-15
CA2253263A1 (en) 1997-11-06
KR20000065223A (ko) 2000-11-06
IL126768A0 (en) 1999-08-17
HUP0100285A3 (en) 2003-05-28
EP0914135A4 (en) 2001-01-24
EP0914135A1 (en) 1999-05-12
NO985065D0 (no) 1998-10-30
NO985065L (no) 1998-12-28

Similar Documents

Publication Publication Date Title
BR9710704A (pt) Uso de inibidores de proteina cinase c para aumentar a efic cia cl¡nica de agentes oncol¡ticos e terapia de radia-Æo
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
BR9706968A (pt) Uso de antagonistas de alfa-ppar e gama-ppar para o tratamento de sindrome x
BR9505408A (pt) Composição terapêutica de aplicacão tópica e utilização de um antagonista de substância P
EE200000658A (et) CD23 antikehad, nende derivaadid ja nende terapeutiline kasutamine
PT984957E (pt) Novas formas de s-omeprazole
EE200300528A (et) Cripto valku blokeerivad antikehad ja nende kasutamine
NO20003067D0 (no) Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling
PT864559E (pt) Compostos amino substituidos e sua utilizacao como substancias activas analgesicas
ID22650A (id) Penggunaan penghambat-penghambat lipase usus lambung
BR9707808A (pt) Composto composição farmacêutica e uso do composto
ID21582A (id) Pasangan pengikat untuk inhibitor kinase tergantung-siklin dan penggunaannya untuk mencari inhibitor dan untuk diagnosis atau terapi suatu penyakit
BR9612413A (pt) Composto uso do mesmo e composição farmacêutica
PT906268E (pt) Fluorenonas com substituicao alquiloxiamino e sua utilizacao como inibidores da proteina quinase c
NO20002346L (no) Ny formulering for bruk i smertebehandling
IS5534A (is) Ný notkun staðdeyfandi efna gegn æðahöfuðverkjum
GB9708067D0 (en) Rapid and long lasting biocidal system and its use to the treatment of hard surfaces
DE69802131D1 (de) Humane Protein-Kinase hYAK3
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine
PT975364E (pt) Formulacao de alergenos
ID30381A (id) Penggunaan arilalkanoilpiridazina
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
ID27014A (id) Metode yang lebih baik untuk pembuatan turunan-turunan norbenzomorfana yang bermanfaat secara farmasi
ID24521A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
FI974235A0 (fi) Ny bestaemningsmetod

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]